THERADIAG : Availability of the 2012 Annual Financial Report

Regulatory News :

THERADIAG (Paris:ALTER) (ISIN : FR0004197747, Ticker : ALTER), a company specializing in theranostic and in vitro diagnostic, today informs its shareholders and the financial community that its 2012 Annual Financial Report for the year to December 31, 2012 is now available to the general public.

This Report can be found on THERADIAG website at www.theradiag.com in the section Investors / Documentation.

Upcoming financial publication:
HY 2013: October 1, 2013 (after market close)

About Theradiag
Backed by its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostic tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag is thus participating in the development of "customized treatment”, which favors the individualization of treatments, the evaluation of their efficiency and the prevention of drug resistance. Theradiag markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter diagnosis solution for patients with autoimmune diseases treated with biotherapies. Theradiag is also developing new diagnostic markers thanks to its microRNA platform, which will allow specific biomarkers to be identified in order to guide therapy and will be first and foremost applied to the treatment of AIDS. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has some 50 employees.

For more information about Theradiag, please visit our website: www.theradiag.com